NDA 11361, held by Schering. Perphenazine.
As of Nov 13, 2026, NDA 11361 (Trilafon), held by Schering, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Trilafon8MG ยท tablet, extended release;oral | Perphenazine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters